Mr. George Achilleos reports

NETRAMARK ENGAGES AM PUBLIC RELATIONS TO SUPPORT STRATEGIC COMMUNICATIONS AND MARKET AWARENESS

Netramark Holdings Inc. has engaged AM Public Relations, a health-care-focused public relations agency specializing in media relations, thought leadership and strategic communications for health care and technology companies.

The engagement is intended to support Netramark's broader communications strategy as the company continues to advance its proprietary NetraAI platform and expand industry relationships. This work with AM PR aims to communicate Netramark's scientific, clinical and commercial progress to key audiences, including investors, potential partners, industry stakeholders and the broader health care community.

"This engagement comes at an important time for Netramark as we continue to build awareness of our platform, our partnerships, and the role NetraAI can play in helping pharmaceutical and biotechnology companies generate more meaningful insights from clinical trial data," said George Achilleos, chief executive officer of Netramark. "As the market increasingly recognizes the need for explainable AI in drug development, we believe it is important to communicate our progress clearly, consistently and to the right audiences. AM Public Relations brings experience in shaping complex stories for broader visibility, and we look forward to working with them as we continue to advance Netramark's strategic objectives."

AM PR specializes in strategic communications for health care and technology companies to communicate complex science, technology and innovation to investors, customers, partners and the media.

"Netramark is tackling one of the biggest challenges in clinical development: helping researchers generate more meaningful insights from complex clinical trial data," said Ashley Moore, founder and chief executive officer of AM PR. "As the company continues to grow, we'll help communicate the science behind the platform, the impact it's having for customers and the broader role explainable AI can play in the future of drug development."

About Netramark Holdings Inc.

Netramark is focused on being a leader in the development of generative artificial intelligence/machine learning solutions that are targeted at the biotechnology and pharmaceutical industries. The company's product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows Netramark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that Netramark can work with much smaller data sets often prevalent in clinical trials, and accurately segment diseases into different types, as well as help to classify patients for sensitivity to drugs and/or efficacy of treatment.

We seek Safe Harbor.